The recent surge in investments into boutique pharmaceutical companies, particularly those focusing on experimental therapies and difficult drug development programs, has fueled what some are calling "High Roller Pharma." While the promise for blockbuster treatments and impressive returns is undeniable, the linked risks are also significant. Many o